Table 1.
Demographics and Clinical Characteristics of Patients in the ICAN Extension Phase (FAS)
| Parameters | ICAN Extension Phase (FAS) (N = 472) |
|---|---|
| Sex | |
| Male | 230 (48.7) |
| Female | 242 (51.3) |
| Median age (range), y | 60 (34–88) |
| Smoking status | |
| Nonsmoker | 308 (65.3) |
| Ex-smoker | 103 (21.8) |
| Smoker | 61 (12.9) |
| Preoperative performance status score | |
| 0 | 410 (86.9) |
| 1 | 54 (11.4) |
| 2 | 8 (1.7) |
| Preoperative stage | |
| Stage IA | 160 (33.9) |
| Stage IB | 151 (32.0) |
| Stage II | 45 (9.5) |
| Stage IIIA | 100 (21.2) |
| Stage IIIB | 9 (1.9) |
| Unknown | 7 (1.5) |
| Surgery type | |
| Lobectomy | 432 (91.5) |
| Local resection | 26 (5.5) |
| Pneumonectomy | 14 (3.0) |
| Postoperative stage | |
| Stage IA | 152 (32.2) |
| Stage IB | 121 (25.6) |
| Stage II | 61 (13.0) |
| Stage IIIA | 132 (28.0) |
| Stage IIIB | 6 (1.3) |
| Neoadjuvant therapy | |
| None | 464 (98.3) |
| Radiotherapy | 1 (0.2) |
| Chemotherapy | 7 (1.5) |
| Paclitaxel + cisplatin or carboplatina | 3 (0.6) |
| Taxotere + cisplatin or carboplatina | 2 (0.4) |
| Docetaxel + carboplatina | 1 (0.2) |
| Pemetrexed disodium for injection + nedaplatina | 1 (0.2) |
| Adjuvant therapy | |
| None | 261 (55.3) |
| Chemotherapy alone or in combination with radiotherapyb | 207 (43.9) |
| Targeted therapy | 4 (0.8) |
Note: Data are presented as number (%) of patients unless otherwise indicated.
FAS, full analysis set.
a
Calculated as percentages of the total number of patients in the ICAN extension phase (N = 472).
b
In the ICAN extension phase, 25 patients received chemotherapy in combination with radiotherapy.